Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor (Nasdaq: DXR) will demonstrate its next-generation Blood Volume Analyzer platform at MedAxiom’s CV Transforum in Denver on October 22–24, 2026. The conference takes place at the Gaylord Rockies Resort & Convention Center.
The FDA 510(k)-cleared, lab-based platform directly measures blood volume. Daxor says it operates three times faster than its predecessor, requires 50% less sample volume and delivers greater than 95% measurement accuracy. Commercial leaders will host demonstrations and discuss clinical workflow integration and institutional return-on-investment models with cardiovascular administrators and clinical leaders.
Daxor (DXR) announced new blood volume analysis study findings and clinician interest following the HFSA 2026 Annual Scientific Meeting. Researchers from Banner University Medical Center presented data on blood volume analysis (BVA), which directly measures plasma volume and red blood cell volume. In patients with left ventricular assist devices or total artificial hearts, standard bedside examinations missed fluid overload and true anemia in 38% of cases. BVA identified these abnormalities, enabling treatment adjustments and a statistically significant improvement in diuresis, or fluid removal through urine (p = 0.02).
A separate 238-patient study examined volume abnormalities in advanced heart failure. Daxor said BVA identified plasma volume reserve depletion linked to red blood cell abnormalities and capillary leak.
Daxor (DXR) will showcase its Blood Volume Analysis platform at ASN Kidney Week in Denver from October 21–25, 2026.
The company's ASN debut will take place at the Colorado Convention Center, with representatives at Booth #390. The FDA-cleared, lab-based diagnostic platform directly measures total blood, red blood cell and plasma volume. Daxor will highlight its use in fluid management for complex kidney care, including dialysis and cardiorenal syndrome. Its team will provide platform overviews and discuss clinical integration and reimbursement pathways.
Daxor (Nasdaq: DXR) will showcase its next-generation Blood Volume Analyzer at the HFSA Annual Scientific Meeting on October 9–12, 2026, in Phoenix. The platform has FDA 510(k) clearance. Daxor says it operates three times faster than its predecessor, BVA-100, requires 50% less blood and delivers greater than 95% measurement accuracy.
Independent clinical investigators will present two ePosters on October 10. One covers inpatient blood volume analysis in patients with left ventricular assist devices or total artificial hearts. The other examines differences in blood volume abnormalities in advanced heart failure, including the role of red blood cell volume. Daxor will also participate in Device Day and offer live product demonstrations at Booth #803.
Daxor Corporation (DXR) will participate in Lake Street's Tenth Annual Best Ideas Growth (BIG10) Conference in New York City on September 10, 2026. CEO and President Michael Feldschuh is scheduled to attend, and management plans to hold one-on-one and small group meetings with investors during the event. Interested investors are directed to their Lake Street contacts or to CORE IR for additional information and registration assistance.
Daxor (Nasdaq: DXR) issued a mid‑year 2026 shareholder letter detailing commercial, financial, and clinical progress. The company completed a $9 million registered direct offering in January 2026 (765,958 shares at $11.75), used mainly to retire $1.17 million of short‑term debt and fund manufacturing and inventory investments.
As of June 30, 2026, unaudited net assets were $51.8 million, up $5.9 million from year‑end, with NAV per share of $8.88 versus $9.07 on December 31, 2025. Daxor reports being debt‑free with 5,838,224 common shares outstanding and no warrants or convertibles. Unaudited kit sales rose 16% year‑over‑year in the first half, while the sales team is being expanded by 300% under a new SVP of Sales.
The company highlighted strong demand for its FDA‑cleared next‑generation Blood Volume Analyzer, new U.S. patent 12,635,917 B2 for remote blood volume monitoring, and clinical data showing substantial reductions in readmissions, mortality, and length of stay when care is guided by its Blood Volume Analysis technology.
Daxor (Nasdaq: DXR) announced the launch of an outpatient Blood Volume Analysis (BVA™) program at a leading healthcare facility in eastern Kansas, expanding its Midwestern outpatient footprint. The program uses Daxor’s turnkey ezBVA Lab CLIA-certified send-out model to deliver 98% accurate, quantitative blood, plasma, and red cell volume measurements within 24 hours without capital equipment or dedicated lab infrastructure.
According to Daxor, the service is designed to replace subjective fluid assessment with objective volume metrics, supporting individualized decongestion strategies that aim to optimize outcomes, safeguard renal function, and reduce hospital readmissions within existing reimbursement structures.
Daxor (Nasdaq: DXR) will exhibit for the first time at the 14th Annual Dysautonomia International Conference, held July 9–12, 2026, at The Woodlands Marriott Waterway Hotel & Convention Center in The Woodlands, Texas.
The company will showcase its FDA-cleared next-generation rapid, lightweight, lab-based Blood Volume Analyzer (BVA™), highlighting how objective plasma and red blood cell volume data may help target dysautonomia therapy and support more data-driven, precision care.
Daxor (Nasdaq: DXR) received U.S. Patent No. 12,635,917 B2 for a Remote Blood Volume Monitor on June 2, 2026. The technology combines baseline blood volume measurement with ongoing hematocrit monitoring via wearable sensors, delivering real-time absolute blood, plasma, and red cell volume data without repeated tracer injections.
The patented system uses algorithms to calculate volume deviations and send predictive alerts when patient-specific thresholds are crossed, supporting management of heart failure, syncope, anemia, and polycythemia. It can also integrate with other monitoring systems, providing euvolemically-corrected data for a more comprehensive physiological overview.
Daxor (Nasdaq: DXR) will exhibit its Blood Volume Analyzer (BVA™) at the MedAxiom CV Transforum Spring’26, April 30–May 2, 2026, at Sawgrass Marriott, Ponte Vedra Beach, FL. The company says the forum supports its commercial strategy to engage cardiovascular decision-makers and accelerate BVA adoption to inform value-based care.
According to the company, peer-reviewed studies link BVA-guided care to large outcome differences: 30‑day mortality down 82%, 1‑year mortality down 86%, 30‑day readmissions down 56%, and 55% shorter length of stay when done on admission (P<0.001).